Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Current Drug Therapy

Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use

Alexa Nicole Fiffick, DO, MBS, NCMP, Tara K. Iyer, MD, NCMP, Tiffany Cochran, MD, MA, NCMP and Pelin Batur, MD, FACP, NCMP
Cleveland Clinic Journal of Medicine March 2023, 90 (3) 181-190; DOI: https://doi.org/10.3949/ccjm.90a.22075
Alexa Nicole Fiffick
Department of Subspecialty Care for Women’s Health, OB/GYN and Women’s Health Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tara K. Iyer
Division of Women’s Health, Department of Medicine, Brigham and Women’s Hospital; Clinical Instructor, Harvard Medical School, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiffany Cochran
Beaufort Jasper Hampton Comprehensive Health Services, Departments of Medicine and Women’s Health, Port Royal Medical Center, Port Royal, SC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pelin Batur
Department of Subspecialty Care for Women’s Health, Ob/Gyn and Women’s Health Institute, Cleveland Clinic, Cleveland, OH; Professor, Ob/Gyn and Reproductive Biology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Deputy Editor, Cleveland Clinic Journal of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Tables

    • View popup
    TABLE 1

    Comparison of commonly used LARCs, all with > 99% efficacya

    BrandLARC typeProgestogen, doseSize, mmFDA-approved duration of useData-supported duration of useBleeding patternsAmenorrhea according to package insertOther clinical pearls
    MirenaLevonorgestrel-IUD52 mg32 x 328 years8 yearsMore likely to have significantly decreased menstrual bleeding and pain, especially after 1 year of use
    Progestin-only methods may be associated with irregular bleeding and
    1 year: 20%
    5 years: 40%
    Approved for treatment of heavy menstrual bleeding
    Can be used as emergency contraception56
    LilettaLevonorgestrel-IUD52 mg32 x 328 years8 yearsspotting1 year: 19%
    5 years: 40%
    More affordable for patients with limited insurance coverage
    KyleenaLevonorgestrel-IUD19.5 mg28 x 305 years5 years1 year: 12%
    5 years: 23%
    Smaller size may be more suitable to nulliparous patients or those with anatomically smaller uterus
    SkylaLevonorgestrel-IUD13.5 mg28 x 303 years3 years1 year: 6%
    3 years: 12%
    ParagardCopper IUDHormone-free32 x 3610 years12 yearsPossible increased amount and duration of menstrual bleedingNo causal relationship establishedCan be used as emergency contraception
    Best for highly effective contraception that is hormone free (ie, after breast cancer)
    When used during age of mid-late 30s, can provide contraception into menopause transition
    NexplanonSubdermal etonogestrel implant68 mg2 x 403 years5 yearsUnpredictable bleeding pattern, though lightens over time for most2 years: 20%Does not require a pelvic examination
    Easy to learn procedure, training via drug company as opposed to clinician
    • ↵a All the contraceptives are the most-effective contraceptive methods; safe in breastfeeding; no long-term effects on fertility, fertility is immediate following discontinuation; safe for women who cannot or prefer not to take estrogen.

    • FDA = US Food and Drug Administration; IUD = intrauterine device; LARC = long-acting reversible contraceptives

    • Based on data from references 5, 6, 53, and 56.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (3)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 3
1 Mar 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
Alexa Nicole Fiffick, Tara K. Iyer, Tiffany Cochran, Pelin Batur
Cleveland Clinic Journal of Medicine Mar 2023, 90 (3) 181-190; DOI: 10.3949/ccjm.90a.22075

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
Alexa Nicole Fiffick, Tara K. Iyer, Tiffany Cochran, Pelin Batur
Cleveland Clinic Journal of Medicine Mar 2023, 90 (3) 181-190; DOI: 10.3949/ccjm.90a.22075
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • NONHORMONAL CONTRACEPTIVE INTRAVAGINAL GEL
    • INTRAVAGINAL RING
    • PROGESTIN-ONLY PILL
    • NEWER ESTROGEN OPTIONS
    • TRANSDERMAL OPTIONS
    • SELF-ADMINISTERED DEPOT MEDROXYPROGESTERONE ACETATE
    • USE OF LONG-ACTING CONTRACEPTIVE DEVICES BEYOND FDA-APPROVED DURATION OF USE
    • KEY MESSAGES
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Reducing the risks when using benzodiazepines to treat insomnia: A public health approach
  • Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
  • A practical guide for buprenorphine initiation in the primary care setting
Show more Current Drug Therapy

Similar Articles

Subjects

  • Family Medicine
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire